151 related articles for article (PubMed ID: 21964531)
21. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
[TBL] [Abstract][Full Text] [Related]
22. Impact of PET staging in limited-stage small-cell lung cancer.
Xanthopoulos EP; Corradetti MN; Mitra N; Fernandes AT; Kim M; Grover S; Christodouleas JP; Evans TL; Stevenson JP; Langer CJ; Lee TT; Pryma DA; Lin LL; Simone CB; Apisarnthanarax S; Rengan R
J Thorac Oncol; 2013 Jul; 8(7):899-905. PubMed ID: 23608814
[TBL] [Abstract][Full Text] [Related]
23. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer.
Dy GK; Bogner PN; Tan W; Demmy TL; Farooq A; Chen H; Yendamuri SS; Nwogu CE; Bushunow PW; Gannon J; Adjei AA; Adjei AA; Ramnath N
J Thorac Oncol; 2014 Feb; 9(2):222-30. PubMed ID: 24419420
[TBL] [Abstract][Full Text] [Related]
25. Node-negative non-small cell lung cancer: pathological staging and survival in 1765 consecutive cases.
Robinson BM; Kennedy C; McLean J; McCaughan BC
J Thorac Oncol; 2011 Oct; 6(10):1691-6. PubMed ID: 21869717
[TBL] [Abstract][Full Text] [Related]
26. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men.
Cerfolio RJ; Bryant AS; Scott E; Sharma M; Robert F; Spencer SA; Garver RI
Chest; 2006 Dec; 130(6):1796-802. PubMed ID: 17166999
[TBL] [Abstract][Full Text] [Related]
27. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
29. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.
Berghmans T; Lafitte JJ; Thiriaux J; VanHoutte P; Lecomte J; Efremidis A; Koumakis G; Giner V; Richez M; Corhay JL; Wackenier P; Lothaire P; Mommen P; Ninane V; Sculier JP;
Lung Cancer; 2004 Sep; 45(3):339-48. PubMed ID: 15301874
[TBL] [Abstract][Full Text] [Related]
30. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
31. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer.
de Marinis F; Pereira JR; Fossella F; Perry MC; Reck M; Salzberg M; Jassem J; Peterson P; Liepa AM; Moore P; Gralla RJ
J Thorac Oncol; 2008 Jan; 3(1):30-6. PubMed ID: 18166838
[TBL] [Abstract][Full Text] [Related]
32. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.
Koike T; Koike T; Yoshiya K; Tsuchida M; Toyabe S
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):372-8. PubMed ID: 23870323
[TBL] [Abstract][Full Text] [Related]
33. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV; Felip E; Besse B; von Pawel J; Mellemgaard A; Reck M; Bosquee L; Chouaid C; Lianes-Barragán P; Paul EM; Ruiz-Soto R; Sigal E; Ottesen LH; Lechevalier T
J Thorac Oncol; 2013 Dec; 8(12):1529-37. PubMed ID: 24389434
[TBL] [Abstract][Full Text] [Related]
34. Lymphatic invasion predicts survival in patients with early node-negative non-small cell lung cancer.
Nentwich MF; Bohn BA; Uzunoglu FG; Reeh M; Quaas A; Grob TJ; Perez D; Kutup A; Bockhorn M; Izbicki JR; Vashist YK
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):781-7. PubMed ID: 23778087
[TBL] [Abstract][Full Text] [Related]
35. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy.
Higgins KA; Chino JP; Ready N; D'Amico TA; Berry MF; Sporn T; Boyd J; Kelsey CR
J Thorac Oncol; 2012 Jul; 7(7):1141-7. PubMed ID: 22617241
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer.
Patel S; Macdonald OK; Suntharalingam M
Cancer; 2009 Feb; 115(4):842-50. PubMed ID: 19117355
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis.
El-Sherif A; Gooding WE; Santos R; Pettiford B; Ferson PF; Fernando HC; Urda SJ; Luketich JD; Landreneau RJ
Ann Thorac Surg; 2006 Aug; 82(2):408-15; discussion 415-6. PubMed ID: 16863738
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival.
Veeramachaneni NK; Battafarano RJ; Meyers BF; Zoole JB; Patterson GA
Eur J Cardiothorac Surg; 2008 Mar; 33(3):466-9. PubMed ID: 18249130
[TBL] [Abstract][Full Text] [Related]
39. Forced expiratory volume in one second as a prognostic factor in advanced non-small cell lung cancer.
Lee JH; Song EM; Sim YS; Ryu YJ; Chang JH
J Thorac Oncol; 2011 Feb; 6(2):305-9. PubMed ID: 21150675
[TBL] [Abstract][Full Text] [Related]
40. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
